NYSE · Health Care

ELI LILLY & CO LLY

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Pharma

Company profile

Business mix

  • The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N.
  • It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma.
  • In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis.
  • Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer’s disease.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 6 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 40.19 FCF 1.17% Buyback 0.57%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Polen Capital Management 5.8% $841.2M 2026-03-31
Edgewood Management 4.1% $637.8M 2026-03-31
Baron Capital Ron Baron 0.2% $78.2M 2026-03-31
Bridgewater Associates Ray Dalio 0.3% $65.1M 2026-03-31
Sands Capital Management Frank Sands 0.1% $30.2M 2026-03-31
Soros Fund Management George Soros 0.2% $20.4M 2026-03-31

Recent trading changes over the last 2 quarters

Net buyers 3 Last 2 13F filing periods
Net reducers 7 Last 2 13F filing periods
Unchanged holders 2 Share count unchanged
Increase amount $106.2M Estimated from net added shares
Reduction amount $4.7B Estimated from net reduced shares
Net share change / base shares -75.2% -5,521,633 / 7,341,413
Bridgewater Associates Ray Dalio 2 filing periods
13F 2025-12-31 Filed 2026-02-13
Major increase Shares 602.0% 13F value change +$70.8M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -3.4% 13F value change -$13.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 10,441 Last 2 periods +60,371 (+578.2%) Total shares 70,812 Value $65.1M
Soros Fund Management George Soros 2 filing periods
13F 2025-12-31 Filed 2026-02-13
New Shares - 13F value change +$24.0M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -0.6% 13F value change -$3.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 2 periods +22,199 (New) Total shares 22,199 Value $20.4M
Baron Capital Ron Baron 2 filing periods
13F 2025-12-31 Filed 2026-02-17
Minor increase Shares 1.0% 13F value change +$27.6M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -1.6% 13F value change -$14.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 85,613 Last 2 periods -547 (-0.6%) Total shares 85,066 Value $78.2M
Polen Capital Management 2 filing periods
13F 2025-12-31 Filed 2026-02-12
Major reduction Shares -23.2% 13F value change +$100.8M
13F 2026-03-31 Filed 2026-05-14
Major reduction Shares -26.6% 13F value change -$498.0M
Settlement As of 13F 2026-03-31 · Filed 2026-05-14
Base shares 1,622,967 Last 2 periods -708,410 (-43.6%) Total shares 914,557 Value $841.2M
Edgewood Management 2 filing periods
13F 2025-12-31 Filed 2026-02-12
Major reduction Shares -42.4% 13F value change -$313.4M
13F 2026-03-31 Filed 2026-05-14
Major reduction Shares -44.8% 13F value change -$711.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-14
Base shares 2,179,428 Last 2 periods -1,485,971 (-68.2%) Total shares 693,457 Value $637.8M
Sands Capital Management Frank Sands 1 filing periods
13F 2026-03-31 Filed 2026-05-08
New Shares - 13F value change +$30.2M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 0 Last 2 periods +32,887 (New) Total shares 32,887 Value $30.2M
Coatue Management Philippe Laffont 2 filing periods
13F 2025-06-30 Filed 2025-08-14
Major reduction Shares -36.1% 13F value change -$60.2M
13F 2025-09-30 Filed 2025-11-14
Sold out Shares -100.0% 13F value change -$91.5M
Settlement As of 13F 2025-09-30 · Filed 2025-11-14
Base shares 183,721 Last 2 periods -183,721 (-100.0%) Total shares 0 Value $0
Tiger Global Management Chase Coleman 2 filing periods
13F 2025-06-30 Filed 2025-08-14
Minor increase Shares 13.2% 13F value change +$75.4M
13F 2025-09-30 Filed 2025-11-14
Sold out Shares -100.0% 13F value change -$1.2B
Settlement As of 13F 2025-09-30 · Filed 2025-11-14
Base shares 1,334,960 Last 2 periods -1,334,960 (-100.0%) Total shares 0 Value $0
Viking Global Investors Andreas Halvorsen 2 filing periods
13F 2025-06-30 Filed 2025-08-14
New Shares - 13F value change +$325.0M
13F 2025-09-30 Filed 2025-11-14
Sold out Shares -100.0% 13F value change -$325.0M
Settlement As of 13F 2025-09-30 · Filed 2025-11-14
Base shares 0 Last 2 periods +0 (New) Total shares 0 Value $0
Duquesne Family Office Stanley Druckenmiller 2 filing periods
13F 2025-06-30 Filed 2025-08-15
Minor increase Shares 6.2% 13F value change +$158
13F 2025-09-30 Filed 2025-11-14
Sold out Shares -100.0% 13F value change -$78,479
Settlement As of 13F 2025-09-30 · Filed 2025-11-14
Base shares 94,830 Last 2 periods -94,830 (-100.0%) Total shares 0 Value $0
GQG Partners Rajiv Jain 2 filing periods
13F 2025-06-30 Filed 2025-08-13
Major reduction Shares -85.1% 13F value change -$1.3B
13F 2025-09-30 Filed 2025-11-13
Major reduction Shares -99.7% 13F value change -$211.9M
Settlement As of 13F 2025-09-30 · Filed 2025-11-13
Base shares 1,829,453 Last 2 periods -1,828,651 (-100.0%) Total shares 802 Value $612,364
Lone Pine Capital Stephen Mandel 2 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$455.8M
13F 2025-06-30 Filed 2025-08-14
Sold out Shares -100.0% 13F value change -$455.8M
Settlement As of 13F 2025-06-30 · Filed 2025-08-14
Base shares 0 Last 2 periods +0 (New) Total shares 0 Value $0

Recent mentions

No public mentions.